Genesis Research Group unveils enhanced US market access data analytics
November 21, 2024 |
Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities to inform US market access strategy. Alongside this, Genesis also announces the appointment of Ki Park as Vice President, Market Access Strategy & Analytics.
This latest development further enhances Genesis Research Group’s integrated, dynamic approach to market access by combining the power of real-world data analytics with accelerated insights from the RPR Platform, which connects to 3,500+ stakeholders across 65+ countries. This unique integration of comprehensive stakeholder intelligence, real-world data analytics, and a differentiated engagement model provides life sciences companies with the rigorous and validated evidence required to enable timely strategic decisions with unprecedented confidence.
Ki Park brings with him over 20 years of US market access experience. His expertise in data analytics and market access will play a crucial role in enabling clients to leverage data and market intelligence to optimize access, from pre-launch through loss of exclusivity, by effectively navigating current and future market trends.
Ki Park, Vice President, Market Access Strategy & Analytics, commented: “Genesis Research Group helps its clients to innovate differently, and I am excited to join the business at a pivotal stage as it expands its capabilities and service offerings.
“The integration of real-world data analytics with the capabilities of RPR™ in the areas of contracting strategy, market assessment, patient affordability program optimization and healthcare policy impact will significantly enhance our clients’ ability to navigate the US market landscape, providing them with validated evidence-based insights necessary for success in today’s competitive environment. Alongside our unique proficiency in gaining insights from relevant stakeholders, Genesis has a superior ability to bolster that information with data, demonstrating what is happening in the real world quickly and efficiently.”
The company’s enhanced access and pricing capabilities deliver key insights on:
- Market potential for a potential launch product or new indication by analyzing the patient journey and assessing the barriers launch products might face by leveraging data analytics coupled with stakeholder input.
- Payer perceptions on product positioning and associated rebate levels can be combined with payer segmentation analytics to understand the opportunity to move share by payers’ ability to control product utilization.
- Patient access and avenues to optimize co-pay assistance programs leveraging within therapeutic area patients’ response to out-of-pocket costs and understand stakeholders’ views on the necessity and impact of such programs.
- Impact of IRA on patient access, leveraging real-world data layered with payer perceptions to assess and test potential scenarios.
David W. Miller, Chief Executive Officer of Genesis Research Group, said: “This expanded offering reflects our commitment to providing our US market access clients with rigorous, actionable insights that empower them to make more informed decisions. By integrating analytics capabilities within our existing framework, we are enhancing our ability to support clients at every stage of their market access journey. On behalf of the whole organization, I warmly welcome Ki and look forward to utilizing his wealth of expertise within the US market access and data analytics landscape.”
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR
Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice…
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice…